Steroids, Azithromycin, Montelukast, and Symbicort (SAMS) for Viral Respiratory Tract Infection Post Allotransplant
Status:
Terminated
Trial end date:
2013-12-30
Target enrollment:
Participant gender:
Summary
For many patients with blood cancers, stem cell transplantation from a family member or from
an unrelated donor remains the only potentially curative option. Unfortunately, up to 40% of
patients develop chronic lung disease after the transplant, which substantially increases the
risk of death in the long-term. Currently, patients with transplant-related lung disease are
treated with some combination of steroids and other immunosuppressant drugs, but only about 1
out of 5 improve.
The importance of our study is that the investigators aim to prevent the development of
transplant-related chronic lung disease in the first place. Because a strong risk factor for
such chronic lung disease is a prior viral respiratory tract infection, the investigators
think there is a window of opportunity to intervene. As soon as "cold and flu" symptoms
start, the investigators will treat patients with a combination of drugs aimed at eliminating
damaging immune responses triggered by the virus. In the absence of such treatment, the
investigators believe these lung-damaging immune responses would persist even after the virus
disappears. Our hope is that preventive treatment might avoid the development of chronic lung
disease, and this would substantially increase long-term survival in our transplant patients.
This is a pilot study. Once feasibility is established, the investigators will seek to expand
this study into a definitive clinical trial.